

APR 29 2005

PTO/SB/21 (04-04)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/822,968	
	Filing Date	April 15, 2005	
	First Named Inventor	Schenk, Dale B.	
	Art Unit	1647	
	Examiner Name	Turner, S. L.	
Total Number of Pages in This Submission	38	Attorney Docket Number	16270J-004773US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Communication (2 pages) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (6 pgs.); PTO/SB/08A (7 pgs.); PTO/SB/08B (24 pgs.) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Townsend and Townsend and Crew LLP Rosemarie L. Celli Reg. No. 42,397
Signature	<i>Rosemarie L. Celli</i>
Date	April 29, 2005

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. (703) 872-9306 on April 29, 2005.	
Typed or printed name	Christopher R. Fitting
Signature	<i>Ch Fitting</i>
Date	April 29, 2005

60479829 v1


APR. 29. 2005 9:21AM

TTC-PA 650-326-2422

RECEIVED
CENTRAL FAX CENTER NO. 6259 P. 2

I hereby certify that this correspondence is being sent by facsimile transmission to: Commissioner for Patents at 703-872-9306

APR 29 2005 **PATENT**
Attorney Docket No.: 15270J-004773US
Client Reference No.: 209-US-CIP8AC4

On April 29, 2005
TOWNSEND and TOWNSEND and CREW LLP
By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/822,968

Filed: April 15, 2005

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Sharon L. Turner

Art Unit: 1647

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of references 1-450, 454-509, 517-542, 545-547, 549-561, 564-569, 571 and 579 can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;

09/497,553 filed 02/03/00;

09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;

09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;

SCHENK, Dale B.
Application No.: 10/822,968
Page 2

PATENT

09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
10/934,609 filed 09/02/04 issue fee paid 01/24/05;
10/933,559 filed 09/02/04 issue fee paid 01/24/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04 issue fee paid 01/24/05;
10/815,404 filed 03/31/04 issue fee paid 11/12/04;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;
10/923,469 filed 08/20/04;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00 issue fee paid 11/12/04;

SCHENK, Dale B.
Application No.: 10/822,968
Page 3

PATENT

09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,929 filed 11/28/00;
09/724,567 filed 11/28/00 issue fee paid 05/24/04;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00 issue fee paid 02/10/05;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);
09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);
issue fee paid 01/28/05; and,
09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

SCHENK, Dale B.
Application No.: 10/822,968
Page 4

PATENT

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 02/27/04;
10/232,030 filed 08/30/02;
10/010,942 filed 12/06/01;
10/388,389 filed 03/12/03;
10/703,713 filed 11/07/03;
10/704,070 filed 11/07/03;
10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04.
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;

SCHENK, Dale B.
Application No.: 10/822,968
Page 5

PATENT

60/251,892 filed 12/06/00;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99; and
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03;
60/444,150 filed 02/01/03; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.

"Grant Application; Raso, Immunology of Alzheimer's Disease', 1/1998," cited by the Examiner in Application No. 09/579,690, is cited herewith as cite no. 304. Application No. 09/579,690 is a commonly owned copending application directed to subject matter related to the instant application. Applicant believes "1/1998" is not the publication date as alleged by the Examiner, but refers to the grant funding cycle. Applicant's further believe the date of public accessibility, if any, is unknown. Applicant wishes to bring to the Examiner's attention that a copy of a grant application believed to have been submitted by Victor Raso for NIH Grant 1 R43

SCHENK, Dale B.
Application No.: 10/822,968
Page 6

PATENT


AGI 5746-01 on August 29, 1997 is cited as cite no. 144. Cite no. 144 is a redacted version of cite no. 304. Applicant obtained cite no. 144 under the Freedom of Information Act (FOIA). It is believed that the grant proposal would not have been accessible under FOIA before April 2, 1998, but the exact date of public accessibility, if any, is not known to Applicant.

The Assignee of the instant application is a licensee of U.S. Patent No. 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Patent No. 5,688,651 and U.S. Application No. 09/441,140 are submitted herewith as Cite Nos. 16 and 283, respectively.

As provided for by 37 CFR §1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf
60475763 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 31

Complete if Known

Application Number	10/822,968
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004773US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	578	6,875,434	04-05-2005	Schenk	
	577	6,866,849	03-15-2005	Schenk	
	575	6,866,850	03-15-2005	Schenk	
	576	6,818,218	11-16-2004	Schenk	
	563	6,787,637	09-07-2004	Schenk et al.	
	572	6,761,888	07-13-2004	Schenk	
	562	6,750,324	06-15-2004	Schenk et al.	
	573	6,743,427	06-01-2004	Schenk	
	442	6,713,450 B2	03-30-2004	Frangione et al.	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	415	2003/0166558 A1	09-04-2003	Frangione et al.	
	431	2003/0165496 A1	09-04-2003	Basi et al.	
	544	2003/0147862 A1	08-07-2003	Solomon et al.	
	432	6,562,341 B2	05-13-2003	Prusiner et al.	
	360	2003/0073655 A1	04-17-2003	Chain	
	440	2003/0068316 A1	04-10-2003	Klein et al.	
	378	2002/0197258 A1	12-26-2002	Ghanbari et al.	
	366	2002/0187157 A1	12-12-2002	Jensen et al.	
	377	2002/0168377 A1	11-14-2002	Schaetzl	
	340	2002/0162129 A1	10-31-2002	Lannfelt	
	395	2002/0160394 A1	10-31-2002	Wu	
	326	2002/0136718 A1	09-26-2002	Raso	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Geffer et al.	
	325	2002/0102261 A1	08-01-2002	Raso	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	306	6,417,178 B1	07-09-2002	Klunk et al.	
	376	2002/0086847 A1	07-04-2002	Chain	
	345	2002/0077288 A1	06-20-2002	Frangione	
	405	6,399,314 B1	06-04-2002	Krishnamurthy	
	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
	342	2002/0009445 A1	01-24-2002	Du et al.	
	511	6,331,440	12-18-2001	Nordstedt, et al.	

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475762 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number 10/822,968

Filing Date April 12, 2004

First Named Inventor Schenk, D. B.

Art Unit 1647

Examiner Name Turner, S. L.

Sheet 2 of 31

Attorney Docket Number 15270J-004773US

416	6,303,567 B1	10-16-2001	Findeis et al.
267	6,294,171 B2	09-25-2001	McMichael
381	2001/0021769 A1	09-13-2001	Prusiner
401	6,284,533 B1	09-04-2001	Thomas
234	6,284,221 B1	09-04-2001	Schenk, et al.
300	2001/0018053 A1	08-30-2001	McMichael
516	6,261,569	07-17-2001	Comis et al.
230	6,262,335 B1	07-17-2001	Hsiao et al.
452	6,218,506 B1	04-17-2001	Krafft et al.
196	6,150,091	11-21-2000	Pandolfo et al.
231	6,114,133	09-05-2000	Seubert et al.
1	6,057,367	05-02-2000	Stamler et al.
510	6,022,859	02-08-2000	Kiessling, et al.
221	5,989,566	11-23-1999	Cobb et al.
417	5,985,242	11-16-1999	Findeis et al.
2	5,958,883	09-28-1999	Snow
3	5,955,317	09-21-1999	Suzuki et al.
4	5,955,079	08-21-1999	Mond et al.
346	5,935,927	08-10-1999	Vitek et al.
512	5,891,991	04-06-1999	Wasco et al.
5	5,877,399	03-02-1999	Hsiao et al.
6	5,869,093	02-09-1999	Weiner et al.
7	5,869,054	02-09-1999	Weiner et al.
445	5,854,215	12-29-1998	Findeis et al.
8	5,854,204	12-29-1998	Findeis et al.
9	5,851,996	12-22-1998	Kilne
10	5,849,298	12-15-1998	Weiner et al.
382	5,846,533	12-08-1998	Prusiner
321	5,837,672	11-17-1998	Schenk et al.
11	5,837,473	11-17-1998	Maggio et al.
353	5,824,322	10-20-1998	Balasubramanian
446	5,817,626	10-06-1998	Findeis et al.
12	5,786,180	07-28-1998	Konig et al.
207	5,780,587	07-14-1998	Potter
357	5,776,468 B1	07-07-1998	Hauser et al.
451	5,766,846	06-18-1998	Schlossmacher et al.
13	5,753,624	05-19-1998	McMichael et al.

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475762 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/822,968
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004773US

Sheet	3	of	31
380	5,750,361	05-12-1998	Prusiner et al.
14	5,750,349	05-12-1998	Suzuki et al.
197	5,744,368	04-28-1998	Goldhaber et al.
211	5,736,142	04-07-1998	Sette et al.
15	5,733,547	03-31-1998	Weiner et al.
373	5,721,130	02-24-1998	Seubert et al.
16	5,688,651	11-18-1997	Solomon
17	5,679,348	10-21-1997	Nesburn et al.
515	5,652,334	07-29-1997	Roberts
18	5,645,820	07-08-1997	Hafler et al.
19	5,641,474	06-24-1997	Hafler et al.
20	5,641,473	06-24-1997	Hafler et al.
356	5,622,701	04-22-1997	Berg
21	5,612,486	03-18-1997	McConlogue et al.
22	5,605,811	02-25-1997	Seubert et al.
320	5,593,846	01-14-1997	Schenk et al.
23	5,585,100	12-17-1996	Mond et al.
358	5,583,112 B2	12-10-1996	Kensil et al.
574	5,576,184	11-19-1996	Better et al.
24	5,571,500	11-05-1996	Hafler et al.
25	5,571,499	11-05-1996	Hafler et al.
513	5,514,548	05-07-1996	Krebbler et al.
514	5,470,951	11-28-1995	Roberts
403	5,464,823	11-07-1995	Lehrer et al.
175	5,441,870	08-15-1995	Seubert, et al.
26	5,434,170	07-18-1995	Andrulis, Jr.
27	5,387,742	02-07-1995	Cordell
543	5,278,049	01-11-1994	Baker et al.
181	5,270,165	12-14-1993	Van Nostrand et al.
284	5,231,170	07-27-1993	Averback
28	5,231,000	07-27-1993	Majocha et al.
29	5,220,013	06-15-1993	Ponte et al.
30	5,208,036	05-04-1993	Eppstein et al.
31	5,192,753	03-09-1993	McGeer et al.
32	5,187,153	02-16-1993	Cordell et al.
548	5,096,706	03-17-1992	Flint

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475762 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 31

Complete if Known

Application Number	10/822,968
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004773US

	33	5,057,540	10-15-1991	Kensil et al.	
	198	5,004,697	04-20-1991	Pardridge	
	570	4,912,206	03-27-1990	Goldgaber et al.	
	402	4,713,366	12-15-1987	Stevens	
	34	4,666,829	05-19-1987	Glenner et al.	

U.S. PATENT APPLICATIONS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	296	60/254,465	12-08-2000	Holtzman et al.	
	297	60/254,498	12-08-2000	Holtzman et al.	
	305	09/724,842	11-28-2000	Chalfour et al.	
	299	60/186,295	03-01-2000	Rasmussen et al.	
	295	60/184,601	02-24-2000	Holtzman et al.	
	282	60/169,687	12-08-1999	Chain	
	242	60/168,594	11-29-1999	Chalfour et al.	
	283	09/441,140	11-16-1999	Solomon et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	533	AU	199870091		07-01-1999			
	343	EP	1 172 378	A1	01-16-2002			
	48	EP	506 785	B1	03-15-2000			
	43	EP	639 081	B1	11-03-1999			
	46	EP	561 087	B1	08-04-1999			
	35	EP	911 036	A2	04-28-1999			
	42	EP	652 962	B1	12-16-1998			
	36	EP	868 918	A2	10-07-1998			
	37	EP	863 211	A1	09-09-1998			
	38	EP	845 270	A1	06-03-1998			
	523	EP	752 886	B1	01-28-1998			
	45	EP	594 607	B1	08-27-1997			
	39	EP	782 859	A1	07-09-1997			
	187	EP	783 104	A1	07-09-1997			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60475762 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/822,968
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004773US

Sheet 5 of 31

47	EP	526 511	B1	05-28-1997			
50	EP	440 619	B1	01-24-1996			
51	EP	359 783	B1	11-29-1995			
40	EP	683 234	A1	11-22-1995			
41	EP	668 080	A1	08-09-1995			
44	EP	613 007	A2	08-31-1994			
52	EP	276 723	B1	12-08-1993			Yes
49	EP	451 700	A1	10-16-1991			
93	GB	2 335 192	A	09-15-1999			
92	GB	2 220 211	A	01-04-1990			
579	WO	04/031400	A2	04-15-2004			
571	WO	04/13172	A2, A3	02-12-2004			
441	WO	03/104437	A2	12-18-2003			
443	WO	03/074081	A1	09-12-2003			
447	WO	03/051374	A2	06-26-2003			
433	WO	03/020212	A2	03-13-2003			
458	WO	02/060481	A1	08-08-2002			
457	WO	02/046237	A1	06-13-2002			
351	WO	02/34878	A2	05-02-2002			
557	WO	02/88307	A2	11-07-2002			
556	WO	02/88306	A2	11-07-2002			
352	WO	02/34777	A1	05-02-2002			
456	WO	02/021141	A2	03-14-2002			
341	WO	02/03911	A2	01-17-2002			
344	WO	01/90182	A2	11-29-2001			
348	WO	01/77167	A2	10-18-2001			
294	WO	01/62801	A2	08-30-2001			
301	WO	01/62284	A2	08-30-2001			
298	WO	01/42306	A2	06-14-2001			
243	WO	01/39796	A2	06-07-2001			
450	WO	01/18169	A3	03-15-2001			
455	WO	01/10900	A2	02-15-2001			
199	WO	00/77178	A1	12-21-2000			
322	WO	00/72880	A2, A3	12-07-2000			
323	WO	00/72876	A2, A3	12-07-2000			
324	WO	00/72870	A1	12-07-2000			
529	WO	00/68263	A2	11-16-2000			

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475762 v1

PTO/SO/08A (10-01)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 31

Complete if Known

Application Number	10/822,988
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Tumer, S. L.
Attorney Docket Number	15270J-004773US

240	WO	00/43039	A1	07-27-2000		
188	WO	00/43049	A1	07-27-2000		
519	WO	00/26238	A2	05-11-2000		
555	WO	00/23082	A1	04-27-2000		
522	WO	00/20027	A2	04-13-2000		
53	WO	99/60024	A1	11-25-1999		
55	WO	99/58564	A1	11-16-1999		
54	WO	99/60021	A2	11-15-1999		
331	WO	99/06545	A2	11-02-1999		
57	WO	99/27949	A1	06-10-1999		
58	WO	99/27944	A1	06-10-1999		
59	WO	99/27911	A1	06-10-1999		
526	WO	99/06587	A2	02-11-1999		
56	WO	99/06066	A2	02-11-1999		
203	WO	99/00150	A2	01-07-1999		
60	WO	98/44955	A1	10-15-1998		
454	WO	98/33815	A1	08-06-1998		
520	WO	98/22120	A1	05-28-1998		
530	WO	98/08868	A1	03-05-1998		
61	WO	98/07850	A2	02-26-1998		
521	WO	98/05350	A1	02-12-1998		
525	WO	98/02462	A1	01-22-1998		
527	WO	97/32017	A1	09-04-1997		
202	WO	97/21728	A1	06-19-1997		
82	WO	97/17613	A1	05-15-1997		
383	WO	97/10505	A1	03-20-1997		
528	WO	97/08320	A1	03-06-1997		
63	WO	96/39176	A1	12-12-1996		
532	WO	96/37621	A2	11-28-1996		
208	WO	96/28471	A1	09-19-1996		
64	WO	96/25435	A1	08-22-1996		
65	WO	96/18900	A1	06-20-1996		
66	WO	95/31996	A1	11-30-1995		
518	WO	95/23166	A1	08-31-1995		
200	WO	95/12815	A1	05-11-1995		
67	WO	95/11994	A1	05-04-1995		
68	WO	95/11311	A1	04-27-1995		
227	WO	95/11008	A2	04-27-1995		

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475762 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

Application Number 10/822,968

Filing Date April 12, 2004

First Named Inventor Schenk, D. B.

Art Unit 1647

Examiner Name Turner, S. L.

Attorney Docket Number 15270J-004773US

Sheet	7	of	31	Attorney Docket Number		15270J-004773US	
	531	WO	95/08999	A1	04-06-1995		
	69	WO	95/05853	A1	03-02-1995		
	524	WO	95/05393	A2	02-23-1995		<input type="checkbox"/>
	70	WO	95/04151	A2	02-09-1995		
	201	WO	94/28412	A1	12-08-1994		
	517	WO	94/05311	A1	03-17-1994		
	71	WO	94/03615	A1	02-17-1994		
	72	WO	94/01772	A1	01-20-1994		
	73	WO	93/21950	A1	11-11-1993		
	74	WO	93/16724	A1	09-02-1993		
	75	WO	93/15760	A1	08-19-1993		
	76	WO	93/14200	A1	07-22-1993		
	205	WO	93/04194	A1	03-04-1993		
	77	WO	93/02189	A1	02-04-1993		
	78	WO	92/13069	A1	08-06-1992		
	79	WO	92/08708	A1	04-30-1992		
	80	WO	92/06187	A1	04-16-1992		
	81	WO	91/19810	A1	12-26-1991		
	82	WO	91/16819	A1	11-14-1991		
	83	WO	91/12816	A1	09-05-1991		
	84	WO	91/08760	A1	06-27-1991		
	85	WO	90/12871	A1	11-01-1990		
	86	WO	90/12870	A1	11-01-1990		
	89	WO	89/06689	A1	07-27-1989		
	88	WO	89/06242	A1	07-13-1989		
	90	WO	89/03687	A1	05-05-1989		
	87	WO	89/01343	A1	02-23-1989		
	91	WO	88/10120	A1	12-29-1988		

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60475762 v1

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 31

Complete if Known

Application Number	10/822,968
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004773US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	391	AGUZZI et al., "Prion research: the next frontiers," <u>Nature</u> , 389:795-798 (1997).	
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid β -Protein (A β) Deposits With Numerous A β -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <u>Glia</u> , 25:324-331 (1999).	
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," <u>Neurobiology of Aging</u> , 21:383-421 (2000).	
	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <u>Neurology</u> , 45:1441-1445 (1995).	<input type="checkbox"/>
	448	ANDREW et al., <u>Current Protocols in Immunology</u> , 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997).	
	484	ARENDIASH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <u>DNA and Cell Biology</u> , 20(11):737-744 (2001).	
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95).	<input type="checkbox"/>
	485	BACSKAI et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <u>Nature Medicine</u> , 7(3):368-372 (2001).	
	504	BALBACH et al., "Amyloid fibril formation by A β_{16-22} , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR," <u>Biochemistry</u> , 39:13748-13759 (2000).	
	176	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).	<input type="checkbox"/>
	550	BARD et al., "Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <u>PNAS</u> , 100(4):2023-2028 (2003).	
	228	BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," <u>J. Mol. Biol.</u> , 225(4):1075-1093 (1992).	
	96	BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).	<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	9	of	31

	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	
	561	BELLOTTI et al., "Application of Monoclonal Anti-Idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <u>Renal Failure</u> , 15(3):365-371 (1993).	
	404	BENJAMINI et al., from <u>IMMUNOLOGY A Short Course</u> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	
	558	BENJAMINI et al., from <u>IMMUNOLOGY A Short Course</u> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.	
	540	BENKIRANE, et al, "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <u>J. Biol. Chem.</u> , 268(23):26279-26285 (1993).	
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> , 29:345-354 (1999).	
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> , 18:764 (1992).	
	97	BLASS, "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999).	<input type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).	<input type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19:939-945 (1997).	<input type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genetic Develop.</u> , 3:102-109 (1993).	<input type="checkbox"/>
	419	BORK et al., "Go hunting in sequence databases but watch out for the traps," <u>Trends in Genetics</u> , 12(10):425-427 (1996).	
	418	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000).	
	420	BRENNER, S. E., "Errors in genome annotation," <u>Trends in Genetics</u> , 15(4):132-133 (1999).	
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	10	of	31

461	BURDICK et al., "Assembly and aggregation properties of synthetic Alzheimer's A β amyloid peptide antigens," <u>J. Biol. Chem.</u> , 267:546-555 (1992).	
327	CAMERON, "Recent Advances in Transgenic Technology," <u>Molecular Biotechnology</u> , 7:253-265 (1997).	
285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharm.</u> , 15:414A-414B (1992).	
421	CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <u>Diabetes & Metabolism (Paris)</u> , 21:3-25 (1995).	
224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm , last updated May 16, 2002.	
102	CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513-7 (1993).	<input type="checkbox"/>
266	CHAPMAN, "Model behavior," <u>Nature</u> , 408:915-916 (2000).	
349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (2003).	
222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)	
332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V \rightarrow F transgenic mice," <u>Progress in Brain Research</u> , 117:327-337 (1998).	
307	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-979 (2000).	
213	CHEN et al., "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> , 125:223-226 (1991).	
542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <u>J. Biol. Chem.</u> , 276(24):21562-70 (2001).	
566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:551-563 (1985).	
302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231, 60475762 v1

PTO/SB/028 (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/822,968
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
(use as many sheets as necessary)			
Sheet	11	of	31

509	CIRrito et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <u>J. Clin. Invest.</u> , 112:321-323 (2000).
462	CO et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <u>J. Immunol.</u> , 148:1149-1154 (1992).
291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000).
333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000).
286	CORDELL, B., " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).
287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).
541	CRIBBS et al., "AID-Erantomers of Beta-Amyloid Exhibit Similar Biological Properties to AII-L-Beta-Amyloids," <u>J. Biol. Chem.</u> , 272:7431-7436 (1997).
293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998).
412	DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003).
489	DEMATTO et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease," <u>PNAS</u> , 98(15):8850-8855 (2001).
214	DEMATTO et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <u>PNAS early edition</u> , 10.1073/pnas.151281398 (2001).
493	DEMATTO et al., "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease," <u>J. Neurochem.</u> , 81:229-236 (2002).
220	Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compns. - comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)
486	DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	12	of	31

436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only
390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," <u>Biochem. J.</u> , 320:563-570 (1996).
363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?," <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).
422	DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(8):248-250 (1998).
318	DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <u>Neurology</u> , 57(5):801-5 (2001).
103	DUFF et al., "Mouse model made," <u>Nature</u> , 373:476-477 (1995).
288	DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).
407	ECK et al., <u>Goodman and Gilman's The pharmacological basis of therapeutics</u> , Chapter 5, pages 77-101 (1996).
475	EL-AGNAF et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur. J. Biochem.</u> , 256(3):560-569 (1998).
225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/18/2002).
226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002).
104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001).
501	ESLER et al., "Point substitution in the central hydrophobic cluster of a human β-amyloid congener disrupts peptide folding and abolishes plaque competence," <u>Biochemistry</u> , 35:13914-13921 (1996).
105	FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 13 of 31

Complete if Known

Application Number	10/822,968
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004773US

328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing," <i>Alzheimer's and Parkinson's Diseases</i> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <i>Neurobiology of Aging</i> , 17(5):809-815 (1996).
539	FINDEIS et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <i>Biochemistry</i> , 38:6791-6800 (1999).
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <i>PNAS</i> , 88:1779-1782 (1991).
108	FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <i>Neurology</i> , 45:1561-1569 (1995).
464	FLOOD et al., "An amyloid β -Protein fragment, A β [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures," <i>Brain Res</i> , 663(2):271-276 (1994).
538	FLOOD, et al., "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein," <i>PNAS</i> , 91:380-384 (1994).
423	FONSECA et al., "The Presence of Isoaspartic Acid in β -Amyloid Plaques Indicates Plaque Age," <i>Experimental Neurology</i> , 157(2):277-288 (1999).
386	FRAUTSCHY et al., "Effects of injected Alzheimer β -amyloid cores in rat brain," <i>PNAS</i> , 88:8362-8366 (1991).
565	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology</i> , fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).
246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <i>Vaccine</i> , 19:2615-2619 (2001).
245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuroimmunology</i> , 95:136-142 (1999).
247	FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <i>PNAS</i> , 97:11455-11459 (2000).
248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>J. of Neuroimmunology</i> , 88:85-90 (1998).

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 14 of 31

Complete if Known

Application Number	10/822,968
Filing Date	April 12, 2004
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Turner, S. L.
Attorney Docket Number	15270J-004773US

244	FRENKEL, et al., "Modulation of Alzheimer's β -amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 106:23-31 (2000).
210	FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).
249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).
364	FURLAN et al., "Vaccination with amyloid- β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <u>Brain</u> , 126:285-291 (2003).
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514):523-527 (1995).
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ₁₋₄₂ ," <u>Annals of the New York Academy of Science</u> , 920:274-284 (2000).
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).
251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990).
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).
252	GEDDES, "N-terminus truncated β -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999).
463	GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <u>Biochem. J.</u> , 282 (Pt 2):517-522 (1992).
470	GIULIAN et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <u>J. Neurosci.</u> , 16 (19):6021-6037 (1996).
253	GIULIAN, et al., "The HHQK Domain of β -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>J. Biol. Chem.</u> , 273:29719-29726 (1998).
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391:851 (1998).

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	15	of	31

114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem. Biophys. Res. Comm.</u> , 122(3): 1131-1135 (1984).
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem. Biophys. Res. Comm.</u> , 120(3): 885-890 (1994).
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).
388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <u>Ann. Rev. Med.</u> , 46:57-65 (1995).
424	GOLDSBY et al., "Vaccines," Chapter 18 from <u>Immunology</u> , 4th Edition, W.H. Freeman and Company, New York, pages 449-465 (2000).
397	GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants," <u>PNAS</u> , 96:3108-3113 (1999).
303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998).
503	GOREVIC et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , 147(2):854-862 (1987).
237	GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996).
190	GRAVINA et al., "Amyloid β Protein (A β) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).
254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?", <u>TINS</u> , 23:114 (2000).
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).
241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <u>Nature</u> , 359(6393):322-325 (1992).
487	HAASS et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?", <u>Nature Neuroscience</u> , 4(9):859-860 (2001).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	16	of	31

118	HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).
182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).
119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).
121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).
255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995).
193	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).
229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2," <u>Immunology</u> , 78:643-649 (1993).
476	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J. Immunol.</u> , 160:1029-1035 (1998).
177	HELMUTH, "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).
559	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma," <u>Eur. J. Immunol.</u> , 9:657-659 (1979).
473	HILBICH et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease," <u>J. Mol. Biol.</u> , 218:149-163 (1991).
471	HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <u>J. Mol. Biol.</u> , 228:460-473 (1992).
236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 201:61-69 (1991).
534	HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60473762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	17	of	31

413	HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	
122	HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	
174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	
256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987).	
546	IRIZARRY et al., "A β Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997).	
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	
192	IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <u>Neuron</u> , 13:45-53 (1994).	
560	JAHLING et al., "Opsonization of Alphaviruses in Hamsters," <u>J. Medical Virology</u> , 12:1-16 (1983).	
374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51 (1995).	
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	
308	JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-982 (2000).	
257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
Sheet 18 of 31	Attorney Docket Number	15270J-004773US	

216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> , 138:373-384 (1991).
334	JOBLING et al., "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767 (1991).
449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and A β ₄₂ deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94:1550-1555 (1997).
371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β -Amyloid Peptide (1-43) in Transfected 293 Cells," <u>Biochem. Biophys. Res. Comm.</u> , 220:710-718 (1996).
347	JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <u>Infection and Immunity</u> , 32(2):497-502 (1981).
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).
128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).
547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>In Vitro</i> ," <u>J. Mol. Biol.</u> , 287:781-796 (1999).
434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).
554	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <u>Protein Engineering</u> , 4(7):773-783 (1991).
258	KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995).
488	KLEIN et al., "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?," <u>Trends in Neurosciences</u> , 24(4):219-224 (2001).
195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the β A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/083 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1847
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	19	of	31

494	KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J. Neurosci.</u> , 22(15):6331-6335 (2002).
465	KOUDINOV et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem. & Biophys. Res. Comm.</u> , 205:1164-1171 (1994).
389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002).
478	KUO et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 257(3):787-791 (1999).
477	LAMBERT et al., "Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins," <u>PNAS</u> , 95:6448-6453 (1998).
489	LAMBERT et al., "Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies," <u>J. Neurochem.</u> , 78:595-605 (2001).
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).
130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249:1527-1532 (1990).
131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).
259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997).
490	LEE et al., "A β immunization: Moving A β peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001).
132	LEMERE et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , 25(part 1), Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).
260	LEMERE, et al., "Nasal A β treatment induces anti-A β antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000).
553	LEMERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R192G) as mucosal adjuvants," <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002).
551	LEVERONE et al., "A β 1-15 is less immunogenic than A β 1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting," <u>Vaccine</u> , 21:2197-2206 (2003).
459	LEVITT, M., "Molecular dynamics of native protein," <u>J. Mol. Biol.</u> , 168:595-620 (1983).

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	20	of	31

481	LEVY et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?," <u>American Neurological Assoc.</u> , 48:553-554 (2000).
184	LI et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159:1383-1392 (1997).
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).
499	LUE et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease," <u>Am. J. Pathol.</u> , 155:853-862 (1999).
502	MAGGIO et al., "Brain Amyloid - A Physicochemical Perspective," <u>Brain Pathology</u> , 6:147-162 (1996).
218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992).
261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994).
263	MANN, et al., "Amyloid β protein ($A\beta$) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $A\beta_{42(43)}$," <u>Annals of Neurology</u> , 40:149-156 (1996).
262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 196:105-108 (1995).
408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).
335	MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001).
545	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β -Amyloid Precursor Protein and Alzheimer's Disease," <u>J. Neuroscience</u> , 16(18):5795-5811 (1996).
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>PNAS</u> , 82:4245-4249 (1985).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patent, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
Sheet 21 of 31	Attorney Docket Number	15270J-004773US	

309	MATTSON, "Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives," <u>Physiol Rev.</u> , 77(4):1081-132 (1997).
135	MC GEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2):197-210 (1997).
264	MC GEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992).
479	MCLEAN et al., "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer. Neurological Assoc.</u> 46:860-866 (1999).
238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-166 (1998).
136	MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995).
265	MENA, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995).
310	MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000).
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).
367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid β -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001).
311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-985 (2000).
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).
233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-1165 (1989).
359	MUNCH et al., "Potential neurotoxic inflammatory response to A β vaccination in humans," <u>J. Neural Transm.</u> , 109:1081-1087 (2002).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1847
		Examiner Name	Turner, S. L.
Sheet 22 of 31	Attorney Docket Number	15270J-004773US	

355	MUNSON eds., <i>Principals of Pharmacology: Basic Concepts & Clinical Applications</i> , pgs. 47-48, Chapman & Hall, New York, New York (1995).	
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <i>Am. J. Pathology</i> , 144(5):1082-1088 (1994).	
354	MUTSCHLER et al., <i>Drug Actions: Basic Principles and Therapeutic Aspects</i> pgs. 7, 11-12, Medpharm Scientific Publishers, Stuttgart, Germany (1995).	
250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <i>Exp. Anim.</i> , 43:711-718 (1995).	
268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (A β) subtypes (A β 40 and A β 42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <i>Neuroscience Letters</i> , 201:151-154 (1995).	
281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <i>J. of Med. Primatology</i> , 27:244-252 (1998).	
439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <i>Can. J. Neurol. Sci.</i> , 18(3 suppl.):424-427 (1991), abstract only	
482	NASLUND et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <i>J. Am. Med. Assoc.</i> , 283:1571 (2000).	
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <i>Am. J. Epidemiol.</i> , 145(11):959-969 (1997).	
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	
235	NEWCOMBE et al., "Solubility characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-488 (1985).	
425	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994).	
350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <i>Nature Medicine</i> , 9(4):448-452 (2003).	
329	NIEMANN, "Transgenic farm animals get off the ground," <i>Transgenic Research</i> , 7:73-75 (1998).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	23	of	31

568	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V _L -V _H and V _L -V _L domain dimmers," <u>PNAS</u> , 82:4592-4596 (1985).
409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995
398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 7:703-707 (2001).
406	PAN et al., "Antibodies to β -Amyloid Decrease the Blood-to-Brain Transfer of β -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):609-615 (2002).
280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987).
140	PARESCCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-555 (September 1996).
141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).
564	PCT Search Report of 12/14/04 for application PCT/US04/02856
437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only
336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).
232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996).
269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996).
491	PODUSLO et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol. Dis.</u> , 8(4):555-567 (2001).
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8):652, column 1, abstract 86406t (1994).
394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993).

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	24	of	31

460	QUEEN et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>PNAS</u> , 86:10029-10033 (1989).	
143	QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).	
497	RAGUSI et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," <u>J. Neurochem.</u> , 70(5):2099-2105 (1998).	
145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	
304	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).	
144	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).	
146	ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	
279	SAITO et al., "Vector-mediated delivery of 125 I-labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the Ab $^{1-40}$ vector complex," <u>PNAS</u> , 92:10227-10231 (1995).	
278	SAITOH, N. et al., "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).	
277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).	
148	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	25	of	31

178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).
270	SCHENK et al., " β -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000).
312	SCHENK et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001).
414	SCHENK, D., "Amyloid- β Immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).
466	SCHWARZMAN et al., "Transthyretin sequesters amyloid β protein and prevents amyloid formation," <u>PNAS</u> , 91:8368-8372 (1994).
536	SELA et al., "Different roles of D-amino acids in immune phenomena," <u>FASEB J.</u> , 11(6):449-456 (1999).
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).
151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).
313	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998).
149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease....." <u>Scientific American</u> , pgs. 68-78 (1991).
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	26	of	31

330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000).
400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," <u>Neurobiology of Aging</u> , 23:1001-1008 (2002).
396	SIGURDSSON et al., "Anti-prion antibodies for prophylaxis following prion exposure in mice," <u>Neurosciences Letters</u> , 336:185-187 (2003).
384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002).
314	SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000).
552	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <u>Am. J. Pathology</u> , 159(2):439-447 (2001).
505	SIMMONS, L., "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> ," <u>Molecular Pharmacology</u> , 45:373-379 (1994).
426	SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <u>Gerontology</u> , 43:79-94 (1997).
438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only
315	SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci.</u> , 920:206-8 (2000).
368	SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992).
337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech.</u> , 18(1):34-39 (2000).
319	SMALL et al., "Alzheimer's disease and Abeta toxicity: from top to bottom," <u>Nat Rev Neurosci.</u> , 2(8):595-8 (2001).
427	SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <u>Nature Biotechnology</u> , 15:1222-1223 (1997).
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3):101-105 (1997).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	27	of	31

185	SOLOMON and et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1998).
186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).
159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).
160	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).
411	SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <u>Progress in Alzheimer's and Parkinson's Diseases</u> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).
161	SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).
162	SOLOMON, B., "New Approach Towards Fast Induction of Anti β -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown).
549	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002).
316	SOTO et al., "Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy," <u>Nature Medicine</u> , 4(7):822-826 (1998).
508	SOTO et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation," <u>J. Biol. Chem.</u> , 270(7):3063-3067 (1995).
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1998).
369	SPOONER et al., "The generation and characterization of potentially therapeutic A β antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002).
271	ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1999).
338	STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <u>The Journal of Neuroscience</u> , 22(17):7380-7388 (2002).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/822,968
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	28	of	31

436	STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <u>FEBS Letters</u> , 264(1):43-47 (1990).
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum Malaria</i> ", <u>N. Engl. J. Med.</u> , 336(2):86-91 (1997).
496	STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", <u>Neuroendocrinology</u> , 58:210-217 (1993).
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).
361	SU et al., "Intravascular infusions of soluble β -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999).
498	SUO et al., "Soluble Alzheimers β -amyloid constricts the cerebral vasculature in vivo" <u>Neuroscience Letters</u> , 257:77-80 (1998).
272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996).
467	TABATON et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Biochem. and Biophys. Res. Comm.</u> , 200(3):1598-1603 (1994).
392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003).
399	TAN et al., "Amyloidosis," <u>Histopathology</u> , 25:403-414 (1994).
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).
472	TELLER et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <u>Nature Medicine</u> , 2(1):93-95 (1996).
339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4299-4303 (1995).
273	THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000).
500	TJERNBERG et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation," <u>J. Biol. Chem.</u> , 274(18):12619-12625 (1999).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60475762 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	29	of	31

	276	TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <u>J. Biol. Chem.</u> , 271:8545-8548 (1996).	
	537	TJERNBERG, et al., "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <u>J. Biol. Chem.</u> , 272(19):12601-12605 (1997).	
	492	TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <u>Neurosci. Lett.</u> 307:101-104 (2001).	
	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).	
	375	TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopathy using end-specific antibodies for A β 40 and A β 42: immunohistochemical evidence for amyloid β protein," <u>Neuroscience Letters</u> , 2002:77-80 (1995).	
	167	VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).	
	535	VAN REGENMORTEL et al., "D-peptides as immunogens and diagnostic reagents," <u>Curr. Opin. Biotechnol.</u> , 9(4):377-382 (1998).	
	317	VEHMAS et al., "beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPsw/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology," <u>DNA Cell Biol.</u> , (11):713-721 (2001).	
	428	VELAZQUEZ et al., "Aspartate residue 7 in amyloid β -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <u>Nature Medicine</u> , 3(1):77-79 (1997).	
	168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).	
	410	VERMA et al., "Gene therapy - promises, problems and prospects," <u>Nature</u> , 389:239-242 (1997).	
	569	VERSHIGORA A. E. ODSHCHAYA IMMYNOLOGIYA, pages 35, 229-231 and 152-153.	
	169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).	
	480	WANG et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <u>Experimental Neurology</u> , 158:328-337 (1999).	
	495	WANG et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <u>Brain Research</u> , 924:133-140 (2002).	
Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
		Attorney Docket Number	15270J-004773US
Sheet	30	of	31

274	WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000).	
171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).	
172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7:695-700 (1997).	
387	WELDON et al., "Neurotoxicity of A β Peptide: Confocal Imaging of Cellular Changes Induced by - Amyloid in Rat CNS <i>In Vivo</i> ," <u>Society for Neuroscience Abstracts</u> , 22(Part 1) (1996).	
429	WELLS, J. A., "Additivity of Mutational Effects in Proteins," <u>Biochemistry</u> , 29(37):8509-8517 (1990).	
180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	
170	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-872 (2000).	
474	WINTER et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1996).	
223	WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 58. (Publication date unknown.)	
468	WISNIEWSKI et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol. Aging</u> , 15(2):143-52 (1994).	
385	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):574-587 (2002).	
219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>PNAS</u> , 82:8729-8732 (1985).	
173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94: 1550-1555 (1997).	
506	WOOD et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4" <u>Biochemistry</u> , 34:724-730 (1995).	
275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/822,968
		Filing Date	April 12, 2004
		First Named Inventor	Schenk, D. B.
		Art Unit	1647
		Examiner Name	Turner, S. L.
Sheet 31 of 31	Attorney Docket Number	15270J-004773US	

567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity," <u>J. Exp. Med.</u> , 132:211-250 (1970).	
507	XU et al., "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease," <u>Mechanisms of Ageing and Development</u> , 94:213-222 (1997).	
292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998).	
430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	
290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001).	
483	ZLOKOVIC et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?," <u>Nature Medicine</u> , 6(7):718-719 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60475762 v1